Patents by Inventor Jason A. Hanko
Jason A. Hanko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9845285Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: GrantFiled: December 3, 2015Date of Patent: December 19, 2017Assignees: CymaBay Therapeutics, Inc., DiaTex, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Publication number: 20160280636Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: ApplicationFiled: December 3, 2015Publication date: September 29, 2016Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Patent number: 9233914Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: GrantFiled: February 25, 2015Date of Patent: January 12, 2016Assignees: CYMABAY THERAPEUTICS, INC., DIATEX, INC.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Publication number: 20150225333Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: ApplicationFiled: February 25, 2015Publication date: August 13, 2015Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Patent number: 8993797Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: GrantFiled: July 10, 2013Date of Patent: March 31, 2015Assignee: Cymabay Therapeutics, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Patent number: 8846731Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogs, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.Type: GrantFiled: October 6, 2011Date of Patent: September 30, 2014Assignee: FerroKin Biosciences, Inc.Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
-
Patent number: 8829197Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.Type: GrantFiled: March 7, 2011Date of Patent: September 9, 2014Assignee: FerroKin Biosciences, Inc.Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
-
Patent number: 8710087Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.Type: GrantFiled: August 4, 2011Date of Patent: April 29, 2014Assignee: Ferrokin Biosciences, Inc.Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
-
Publication number: 20140024852Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: ApplicationFiled: July 10, 2013Publication date: January 23, 2014Applicants: Diatex, Inc., Metabolex, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Patent number: 8507719Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: GrantFiled: May 11, 2012Date of Patent: August 13, 2013Assignees: Metabolex, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Publication number: 20130158264Abstract: Polymorphic forms of the tyrosine kinase inhibitor OSI-906, preparation, pharmaceutical compositions, and uses thereof. The invention includes methods of treating diseases such as cancer, including cancer mediated at least in part by IGF-1 R and/or IR, with the polymorphs and compositions. This Abstract is not limiting of the invention.Type: ApplicationFiled: June 23, 2011Publication date: June 20, 2013Inventors: Arlindo L. Castelhano, David A. Enger, Jason A. Hanko, Josef A. Rechka, Jing Teng, Yonglai Yang
-
Publication number: 20120270911Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.Type: ApplicationFiled: October 6, 2011Publication date: October 25, 2012Applicant: FERROKIN BIOSCIENCES, INC.Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
-
Publication number: 20120232303Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: ApplicationFiled: May 11, 2012Publication date: September 13, 2012Applicants: Diatex, Inc., Metabolex, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Publication number: 20120202857Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.Type: ApplicationFiled: August 4, 2011Publication date: August 9, 2012Applicant: FERROKIN BIOSCIENCES, INC.Inventors: Amy E. Tapper, Hugh Y. Rienhoff, JR., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
-
Publication number: 20120196895Abstract: The invention relates to novel crystalline forms of (2RS)-1-(4-ethylphenyl)-2-methyl-3-piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotonic conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension.Type: ApplicationFiled: January 11, 2010Publication date: August 2, 2012Applicant: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Jason A. Hanko
-
Patent number: 8203019Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: GrantFiled: April 20, 2006Date of Patent: June 19, 2012Assignees: Metabolex, Inc., DiaTex, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Patent number: 8063227Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.Type: GrantFiled: July 14, 2009Date of Patent: November 22, 2011Assignee: Ferrokin Biosciences, Inc.Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
-
Publication number: 20110281911Abstract: The invention relates to substantially enantiopure crystalline salt forms of (2RS)-I-(4-Ethylphenyl)-2-methyl-3-piperidin-1-ylpropan-1-one. The preparation and characterization of the substantially enantiopure crystalline salt forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the substantially enantiopure crystalline salt forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotome conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension.Type: ApplicationFiled: August 3, 2009Publication date: November 17, 2011Applicant: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Jason A. Hanko, Jeffrey P. Kiplinger
-
Publication number: 20110275679Abstract: The invention relates to crystalline forms of flupirtine, particularly to 1:1 flupirtine hydrochloride maleic acid cocrystal. The preparation and characterization of 1:1 flupirtine hydrochloride maleic acid cocrystal is described. The invention also relates to the therapeutic use of the flupirtine hydrochloride maleic acid cocrystal to treat nervous system disorders, pain disorders, and musculoskeletal disorders and to pharmaceutical compositions containing the cocrystal.Type: ApplicationFiled: August 6, 2009Publication date: November 10, 2011Applicant: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, Dimitris Kalofonos, Patrick G. Stahly, Jeffrey S. Stults, Jason A. Hanko, Rex A. Shipplett, William Martin-Doyle
-
Patent number: 8003684Abstract: Crystalline forms of (+)-R-zileuton, which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of (+)-R-zileuton are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline (+)-R-zileuton, and using it to inhibit 5-lipoxygenase activity in subjects to treat a number of diseases, are also discussed.Type: GrantFiled: February 21, 2007Date of Patent: August 23, 2011Assignee: Cornerstone Therapeutics, Inc.Inventor: Jason A. Hanko